Endocrine Abstracts

Several studies have identified a relationship between oncogene activation and dedifferentiation of PTC. Mutations of RAS, RET/PTC and BRAF modulate the expression of thyroid genes. An impaired NIS expression has been demonstrated in PTCs harboring the BRAFV600E mutation.Aim of this study was to analyze BRAF and RET/PTC1-3 alterations and their influence on the expression of thyroid differentiation genes. Seventy-one PTC samples were studied. Quantitative analysis o...

18FDG-PET is based on the capability of tumor cells to take up glucose. An increment in expression of the glucose transporter 1 (GLUT1) has been observed in thyroid tumors with poor prognosis but very few data are available about the expression of other glucose transporters in thyroid. Here, we study the expression and function of GLUT isoforms 1, 2, 3, 4, 6, 8, 10, 12 in human thyroid carcinoma cell lines ARO and FRO (anaplastic carcinoma), NPA (poorly-differentiated papillar...

Germline point mutations of the RET proto-oncogene are causative of hereditary MTC. Somatic mutations are described in 40% of sporadic MTCs. Although a relationship between somatic mutations and bad prognosis has been described, data are controversial.No date on the prognostic value of RET polymorphisms are available.Aim of the work was to verify if the presence of a somatic RET mutation and or a polymorphisms can influence the prognosis of MTC. This stu...

Although 20% of follicular neoplasms are papillary thyroid carcinoma (PTC), their cytological diagnosis is not diagnostic. A different profile of gene expression between malignant and benign thyroid tumors has been reported. Aim of this study was to identify a gene expression profile to be used in distinguishing malignant from benign thyroid neoplasms. By real-time RT-PCR we analyzed mRNA expression of 6 thyroid differentiation genes (TTF-1, PAX8, TPO, TSHr, NIS and Tg) and 5 ...